A clinical study of the efficacy of 5HT3 receptor antagonist (palonocetron) in malignant lymphoma patients treated with (R-)CHOP regime
Not Applicable
- Conditions
- Malignant Lymphoma
- Registration Number
- JPRN-UMIN000011092
- Lead Sponsor
- Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
- Brief Summary
The primary endpoint was the overall occurrence rate of nausea, vomiting, and anorexia; these rates were 56%, 12%, and 62%, respectively, including all grades.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)The patients who will have nausea and vomiting except for chemotherapy 2)The patients who have contraindication to use palonocetron 3)The patients who need to reduce CHOP regimen 4)The patients who need to reduce or stop to use prednisolone 5)The patients who are HIV antibody positive, HBs antigen positive, or HCV antibody positive 6)The patients whose doctor judge as ineligible
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The incidence of nausea, vomiting, and anorexia
- Secondary Outcome Measures
Name Time Method